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AbstrAct
ObjeCtive
To establish the extent to which systematic reviews 
and meta-analyses of individual participant data (IPD) 
are being used to inform the recommendations 
included in published clinical guidelines.
Design
Descriptive study.
setting
Database maintained by the Cochrane IPD Meta-
analysis Methods Group, supplemented by records of 
published IPD meta-analyses held in a separate 
database.
POPulatiOn
A test sample of systematic reviews of randomised 
controlled trials that included a meta-analysis of IPD, 
and a separate sample of clinical guidelines, matched to 
the IPD meta-analyses according to medical condition, 
interventions, populations, and dates of publication.
Data extraCtiOn
Descriptive information on each guideline was extracted 
along with evidence showing use or critical appraisal, or 
both, of the IPD meta-analysis within the guideline; 
recommendations based directly on its findings and the 
use of other systematic reviews in the guideline.
results
Based on 33 IPD meta-analyses and 177 eligible, 
matched clinical guidelines there was evidence that 
IPD meta-analyses were being under-utilised. Only 66 
guidelines (37%) cited a matched IPD meta-analysis. 
Around a third of these (n=22, 34%) had critically 
appraised the IPD meta-analysis. Recommendations 
based directly on the matched IPD meta-analyses were 
identified for only 18 of the 66 guidelines (27%). For 
the guidelines that did not cite a matched IPD 
meta-analysis (n=111, 63%), search dates had 
preceded the publication of the IPD meta-analysis in 
23 cases (21%); however, for the remainder, there was 
no obvious reasons why the IPD meta-analysis had not 
been cited.
COnClusiOns
Our results indicate that systematic reviews and 
meta-analyses based on IPD are being under-utilised. 
Guideline developers should routinely seek good quality 
and up to date IPD meta-analyses to inform guidelines. 
Increased use of IPD meta-analyses could lead to 
improved guidelines ensuring that routine patient care is 
based on the most reliable evidence available.
Introduction
Systematic reviews have enormous potential value in 
developing healthcare policy and clinical guidelines, as 
well as directly providing clear and reliable evidence to 
those making clinical decisions. Individual participant 
data (IPD) meta-analyses are commonly described as 
the gold standard of systematic reviews. Unlike system-
atic reviews and meta-analyses based on aggregate data 
(which is usually extracted from study reports) the 
results of IPD meta-analyses are not so restricted by 
many of the well documented publication or reporting 
biases that can hamper other non-IPD systematic 
reviews.1–5 They often include greater numbers of 
patients from more trials, both published and unpub-
lished, providing more reliable summaries of trial 
results. Furthermore, using comprehensive IPD can 
generate more detailed results. For example, the data 
can be better used to test whether the effect of a given 
treatment differs in one type of patients compared with 
another (treatment-covariate interactions), thus poten-
tially enabling better targeting of treatments within spe-
cific patient populations. Detailed information on the 
exact timing of particular outcomes also allows for a 
proper assessment of how any treatment benefits (or 
hazards) might evolve with duration of treatment (treat-
ment-time interactions). Consequently, systematic 
reviews and meta-analyses of IPD can provide key evi-
dence to inform and influence clinical guidance.
Yet despite this clear potential, the extent to which 
IPD meta-analyses, are actually used in practice by 
guideline developers, as best or level 1 evidence,6 is 
uncertain. Therefore, following an international 
workshop of 31 people drawn from the members of the 
Cochrane IPD Meta-analysis Methods Group (Septem-
ber 2012, London), we assessed whether and how 
such meta-analyses are used in published clinical 
guidelines.
WhAt Is AlreAdy knoWn on thIs topIc
Systematic reviews that utilise individual participant data (IPD) are considered to 
be the gold standard in evidence synthesis
Systematic reviews and meta-analyses of IPD may provide key evidence to inform 
clinical guideline recommendations
The extent to which IPD meta-analyses are taken up in clinical guidelines was unclear
WhAt thIs study Adds
Systematic reviews using IPD are being underused in current clinical guidelines
Authors of reviews using IPD could be more proactive in disseminating key findings 
to increase their uptake in clinical guidelines
Guidelines should report key methods and evidence used to underpin treatment 
recommendations consistently and transparently
 open accessRESEARCH
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We identified where practice recommendations had 
been based on evidence from IPD meta-analyses and 
ascertained whether findings from such meta-analyses 
were given precedence over systematic reviews using 
aggregated data and dealing with the same question, 
given the known advantages of using IPD.7–9 Our ulti-
mate intention was to help inform those conducting IPD 
meta-analyses and those developing guidance, on how 
to optimise the uptake and use of these meta-analyses.
Methods
study sample identification
Systematic reviews and meta-analyses of IPD—We 
extracted these from a database maintained by the 
Cochrane IPD Meta-analysis Methods Group,10 supple-
mented by records of published IPD meta-analyses held 
in a separate database.11 To be included in our study, the 
meta-analyses should have been published either in the 
Cochrane Library12 or in a peer reviewed journal 
between 1 January 2008 and 31 December 2010 and car-
ried out a meta-analysis of IPD as part of a full system-
atic review of randomised controlled trials. They should 
have evaluated at least one treatment intervention, irre-
spective of healthcare area or geographical region.
Clinical guidelines—We searched the US National 
Guideline Clearinghouse;13 the Scottish Intercollegiate 
Guidelines Network,14 and the UK National Institute for 
Health and Care Excellence15 websites for all current 
clinical guidelines in healthcare areas relating to our 
sample of IPD meta-analyses. For guidelines related to 
cancer treatments, we also searched the Standards and 
Guidelines Evidence directory of cancer guidelines.16 Eli-
gible guidelines should have been published either orig-
inally or in an updated form between 1 January 2010 and 
31 December 2013, a timeframe that was chosen to allow 
for the inclusion of IPD meta-analyses from our sample; 
albeit that we accepted a one year overlap between pub-
lication of guidelines and meta-analyses in 2010. This 
was done primarily to identify references to the IPD 
meta-analyses published in 2008–09. Two authors 
(LHMR and CLV) matched all potentially eligible guide-
lines to the IPD meta-analyses included in the sample. 
Guidelines were matched to the meta-analyses if they 
dealt with the same medical condition, treatment type, 
and patient populations (for example, adults or chil-
dren). We also included guidelines with a broad scope 
that encompassed the subject area of the meta-analysis. 
Matched guidelines were necessarily published after the 
publication date of the meta-analysis. Duplicate guide-
lines (that is, those identified from more than one 
source) were removed. Two authors (LHMR and CLV) 
resolved queries on the suitability of individual guide-
lines for inclusion in the sample by discussion.
Data extraction
For each matched clinical guideline, we extracted infor-
mation on the guideline developer, date of publication, 
and free availability of the guideline. We also carried out 
a thorough text search of each guideline to identify any 
reference to the matched IPD meta-analyses, using search 
terms including the authors’ names, name of intervention, 
systematic review, meta-analysis, individual patient or 
participant data, and IPD. Furthermore, we sought data 
on whether any other IPD meta-analysis or meta-analysis 
of aggregate data was cited, and any key recommenda-
tions within the guideline that were attributed to a 
matched IPD meta-analysis. Two authors (LHMR and 
CLV) resolved any discrepancies by discussion.
analysis
For each meta-analysis in the test sample, we recorded 
the total number and proportion of unique, matched 
guidelines that cited it. For each cited meta-analysis, we 
looked for evidence within the guideline that it had 
been critically appraised and whether specific practice 
recommendations had been based on the findings of 
the meta-analysis. We also noted whether any other 
related IPD meta-analyses or meta-analyses based on 
aggregate data had been cited, and where both types of 
meta-analyses were cited we looked for evidence that 
any distinction had been made between the two. 
Finally, for guidelines that did not cite the matched IPD 
meta-analysis, we looked for any likely reasons why it 
had not been included or for information about alterna-
tive evidence sources that had been used to inform the 
guideline recommendations.
To obtain overall totals, averages, and frequencies on 
which interpretation could be based we collated data 
from each of the IPD meta-analyses across our test sam-
ple, including the frequency of citations and the num-
ber of guidelines that based their recommendations on 
results of a matched IPD meta-analysis.
results
sample selection
Our two chosen data sources yielded 33 eligible IPD 
meta-analyses published between 2008 and 2010 
Individual participant data (IPD) meta-analysis sources searched:
  Cochrane IPD Meta-analysis Methods Group  database (n=￿•￿)
  Richard Riley database (n=￿￿)
Outside sample date range ( --•-￿-) (n=￿￿€)
Total IPD meta-analyses across databases (n= ￿•)
Duplicate IPD meta-analyses (n=€)
IPD meta-analyses screened (n=ƒ￿)
Ineligible (n=￿„):
  Not based on a systematic review (n=￿-)
  Not a treatment intervention (n=„)
IPD meta-analyses identi‡ed (n=￿ˆ)
Potentially eligible IPD meta-analyses (n=￿￿)
Ineligible (n= ):
  Multiple conditions (n=￿)
  Not a full review (protocol) (n=￿)
Eligible IPD meta-analyses (n=￿￿)
Fig 1 | identification of eligible iPD meta-analysesRESEARCH
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  (fig 1 and table). Fourteen were reviews of cancer 
treatments and eight were reviews of interventions 
related to cardiovascular disorders, mainly stroke 
and heart disease. The remaining 11 reviews covered 
a broad range of healthcare areas, including epi-
lepsy, gynaecological disorders, otitis media, and 
asthma.
Quality of included meta-analyses
Each IPD meta-analysis was conducted as part of a full 
systematic review. In general, across the 33 meta-analy-
ses, the systematic searches had looked across numer-
ous sources (bibliographic databases, Cochrane 
Library, conference proceedings, and reference lists). 
Many (21/33) had also searched trials registers or con-
Description of individual patient data meta-analyses included in sample
Meta-analyses Condition Main treatment comparisons
Matched eligible guidelines
total no 
identified
no (%) citing 
iPD meta- 
analysis
Early Breast Cancer Trialists’ 
Collaborative Group18
Breast cancer: ductal carcinoma in 
situ
Surgery+adjuvant radiotherapy versus surgery alone 12 1 (8)
Early Breast Cancer Trialists’ 
Collaborative Group19 
Breast cancer: metastatic Surgery+adjuvant chemotherapy versus surgery alone 7 2 (29)
Dowsett et al20  Breast cancer: oestrogen receptor 
poor
Adjuvant aromatase inhibitors (with or without tamoxifen) 
versus tamoxifen alone
15 3 (20)
Piccart-Gebhart et al21  Breast cancer Taxanes alone, or in combination with anthracyclines 6 1 (17)
Chemoradiotherapy for Cervical 
Cancer Meta-Analysis Collaboration22 
Cervical cancer Concomitant chemoradiotherapy versus radiotherapy 6 5 (83)
Eden et al23  Childhood acute lymphoblastic 
leukaemia
Vincristine+steroid pulses versus maintenance treatment 1 0 (0)
Childhood Acute Lymphoblastic 
Leukaemia Collaborative Group24 
Childhood acute lymphoblastic 
leukaemia
Anthracyclines+standard therapy versus standard therapy 1 0 (0)
Uronis et al25  Dyspnoea (in cancer) Oxygen versus medical air 1 0 (0)
Baujat et al26  Head and neck cancer: locally 
advanced
Conventional radiotherapy versus hyperfractionated 
radiotherapy or accelerated radiotherapy, or both
8 4 (50)
Pignon et al27  Head and neck cancer: locally 
advanced
Locoregional treatment+chemotherapy versus locoregional 
treatment alone
8 6 (75)
Greb et al28  Non-Hodgkin’s lymphoma High dose chemotherapy with autologous stem cell 
transplantation versus standard dose chemotherapy
8 4 (50)
Auperin et al29  Non-small cell lung cancer: locally 
advanced
Concomitant versus sequential chemoradiotherapy 13 7 (54)
NSCLC Meta-analysis Collaborative 
Group30 
Non-small cell lung cancer Locoregional treatment+adjuvant chemotherapy versus 
locoregional treatment alone
15 3 (20)
NSCLC Meta-analysis Collaborative 
Group31 
Non-small cell lung cancer: advanced Chemotherapy+supportive care versus supportive care alone 6 1 (17)
De Luca et al32  Angioplasty Glycoprotein IIb-IIIa inhibitors administered early versus late 1 0 (0)
Bejan-Angoulvant et al33  Hypertension Active treatment versus no treatment or placebo 3 1 (33)
De Backer Tine et al34  Intermittent claudication Oral naftidrofuryl versus placebo 2 0 (0)
Cholesterol Treatment Trialists’ 
Collaboration35 
Low density lipoprotein cholesterol 
lowering in cardiovascular disease 
prevention
Statins versus control; more intensive versus less intensive 
statin regimens
14 6 (43)
Antithrombotic Trialists’ 
Collaboration36 
Primary and secondary prevention of 
cardiovascular disease
Long term aspirin versus control 16 14 (88)
Halkes et al37  Secondary prevention  of stroke Dipyridamole+aspirin versus aspirin 5 1 (20)
Craig et al38  Stroke Very early mobilisation versus usual stroke care 3 0 (0)
Ellis et al39  Stroke Stroke liaison workers versus usual stroke care 4 1 (25)
Browning et al40  Otitis media in children Grommet insertion versus myringotomy or non-surgical 
treatment
0 Not 
applicable
Koopman et al41  Otitis media in children Antibiotic treatment versus placebo or no (antibiotic) 
treatment
0 Not 
applicable
Kassai et al42  Severe myoclonic epilepsy in infancy Stiripentol versus placebo 1 0 (0)
Ford et al43  Dyspepsia Helicobacter pylori “test and treat” versus empirical acid 
suppression
2 1 (50)
Daniels et al44  Gynaecological: chronic pelvic pain Laparoscopic uterosacral nerve ablation (LUNA) versus 
diagnostic laparoscopy or laparoscopic excision or ablation
0 No 
applicable
Middleton et al45 Gynaecological: heavy menstrual 
bleeding
Hysterectomy versus endometrial destruction (1st or 2nd 
generation) or levonongesterol releasing intrauterine system 
(MIRENA); endometrial destruction versus MIRENA; 1st 
versus 2nd generation endometrial destruction
1 1 (100)
Cools et al46  Neonatal care: preterm infants Elective high frequency oscillatory versus conventional 
ventilation
0 Not 
applicable
Cates et al47  Asthma Regular treatment with salmeterol versus placebo or regular 
short acting β agonists
5 1 (20)
Young et al48  Rhinosinusitis Antibiotic treatment versus placebo 3 1 (33)
Wang et al49  Smoking cessation Nicotine replacement therapy versus placebo 7 0 (0)
O’Meara et al50  Venous leg ulcers: wound care Four layer versus short stretch bandage 3 2 (67)RESEARCH
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sulted with relevant experts to identify unpublished or 
ongoing trials, of which 13 had identified and included 
data from one or more unpublished trials. Most of the 
meta-analyses (26/33) reported either having conducted 
a quality assessment of the included trials, either using 
a recognised tool (for example, Cochrane risk of bias 
tool)17 or thoroughly checking and verifying the validity 
of the data received. Where reported, the IPD meta-anal-
yses were able to include most of the trials identified 
(median 86%, range 56–100%) and also of the known 
randomised patients (median 92%, range 65–100%). 
Methods of analyses used were generally well described 
and in keeping with the outcomes being analysed, and 
many had  prespecified and reported patient level sub-
group analyses in addition to the primary and second-
ary outcomes.
guideline sample selection
Our search of clinical guidelines published between 
2010 and 2013 yielded 1171 records (fig 2); however, 
many of these (n=432, 37%) were identified as out of 
scope based on their titles or guideline summaries, or 
both (for example, unrelated disease or treatment, or 
both, or outside the date range) and were excluded. 
Duplicate records obtained from more than one guide-
line source, (n=201, 17%) were also discarded. The 
remaining 538 potentially eligible guidelines were 
examined in detail. Of these, a further 308 were either 
found to be ineligible (fig 2) or were excluded for other 
reasons (n=53)—for example, because a new guideline 
had superseded the original (n=18) or because the 
guideline was not freely available (n=7). Therefore, 
results are based on 177 guidelines published between 
2010 and 2013 in clinical areas and populations match-
ing those in the sample of IPD meta-analysis.
The 177 guidelines had been written by 43 (see sup-
plementary appendix 1) different guideline develop-
ment groups (range 1–8 per developer) and spanned 
most geographical areas, albeit half (n=89, 50%) were 
North American guidelines. A further 36% (n=64) were 
from the United Kingdom and Europe, with the remain-
der being largely from Australia, New Zealand, and 
Asia. A matched IPD meta-analysis was cited in 66 of 
the 177 guidelines (37%). A third of these guidelines 
(n=22, 34%) had included some critical appraisal of the 
matched meta-analysis. The box and supplementary 
table provide examples of guideline recommendations 
that could be directly attributed to the findings of cited 
IPD meta-analyses.
Of the 177 guidelines, 69 (39%) cited a systematic 
review and meta-analysis of aggregate data either along-
side the matched IPD meta-analysis (n=29, 42%) or 
alone. Where both were cited, few guidelines (n=4, 14%) 
made any distinction between the two systematic 
reviews—for example, by explicitly stating that one was 
based on individual patient data. There was no evidence 
that IPD meta-analyses were more or less likely to be 
included in guidelines from particular geographical 
locations. We saw no clear evidence that the uptake of 
individual IPD meta-analyses depended on the length of 
time since publication. However, the time to uptake in a 
specific guideline will vary according to the frequency 
with which the guidelines are produced or updated. In 
addition, certain guideline developers seemed more 
likely than others to cite IPD meta-analyses. More than 
half of the citations of matched IPD meta-analyses 
(35/66, 53%) were included in guidelines produced by 
only seven of the 43 guideline developers in the sample 
(see supplementary figure 1), whereas 13/43 guideline 
development groups (responsible for 31/177 guidelines) 
did not cite any of the eligible meta-analyses.
Matched guidelines were identified for 29 of the 33 
meta-analyses included in the sample, with a median of 
five guidelines for each meta-analysis. The highest num-
ber of matched guidelines was for one meta-analysis in 
non-small cell lung cancer, for which 16 matched guide-
lines were identified. Of the 29 meta-analyses with 
matched guidelines, 21 (72%) had been cited in at least 
one guideline (median 3, range 1–14 guidelines) and eight 
(28%) were not cited in any of the matched guidelines. Of 
the 21 meta-analyses that were cited, only five were men-
tioned in more than half of the relevant guidelines (table).
Importantly, around two thirds of the guidelines in 
our sample (n=111, 63%) did not cite any IPD meta-anal-
ysis, despite one being available in every case. Three of 
these guidelines (2%) had referenced another guideline 
as their primary evidence source, and on further investi-
gation it was clear that the guideline referenced had 
used an IPD meta-analysis. For 23 guidelines (21%) we 
found that the search dates had preceded the publica-
tion date of the IPD meta-analysis. A further 11 guide-
lines (10%) did not supply their evidence sources in a 
reference list and so we were unable to tell what had led 
to their recommendations. However, for the rest (n=74, 
67%) we could find no obvious reasons why the IPD 
meta-analysis had not been cited. Although we did not 
Guideline sources searched:
  Standards and Guidelines Evidence (n=￿￿￿)
  National Guideline Clearinghouse (n=￿￿￿)
Scottish Intecollegiate Guidelines Network (n=￿￿)
National Institute for Health and Care Excellence (n=￿￿)
Total guidelines screened (n=￿￿￿￿)
Potentially eligible guidelines evaluated (n=￿￿ƒ)
Eligible included guidelines (n=￿￿￿)
Eligible guidelines (n=￿￿„)
Not potentially eligible (n=￿￿†):
  Out of sample date range, unrelated disease or treatment type (n=†￿￿)
  Duplicate guideline (n=￿„￿)
Excluded from survey sample (n=￿￿):
  Superceded by a more recent version (n=￿ƒ)
  Duplicate guideline (across all reviews) (n=￿￿)
  Eligibility unclear (unable to determine if relevant to IPD meta-analysis question) (n=￿)
  Guideline not accessible to determine eligibility (n=￿)
Ineligible (n=￿„ƒ):
  Not a relevant condition or stage of disease (n=￿￿†)
  Not a relevant treatment intervention (n=￿„￿)
  Not a treatment intervention (n=￿ƒ)
  Not a relevant patient population (n=￿†)
  Guideline stated as, but not actually, updated in searches (n=￿)
Fig 2 | identification of eligible guidelinesRESEARCH
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carry out any formal quality appraisal for the included 
guidelines, we did seek information from either the indi-
vidual guideline developers’ handbooks or their web-
sites as to whether they advocated the use of the 
appraisal of guidelines for research and evaluation 
(AGREE) tool51 52 for guideline development or the grad-
ing of recommendations assessment, development, and 
evaluation (GRADE)53 system for appraising the quality 
of the included evidence. Of the 43 guideline develop-
ment groups, we found that 14 guideline developers 
exaMPles OF guiDeline reCOMMenDatiOns linkeD tO FinDings OF CiteD iPD Meta-analyses
example 1*: concomitant chemoradiation for cervical cancer22
Potential impact—making recommendations about specific treatment regimens
the iPD meta-analysis
•	15 randomised trials, 3452 patients
Pertinent results
•	6% survival benefit at five years associated with chemoradiation
•	No suggestion of a difference between the treatment benefit, whether platinum based or non-platinum based treatment regimens
recommendations in guidelines citing iPD meta-analysis
•	Concomitant chemoradiation represents the standard
•	Non-platinum based regimens for chemoradiation seem to be as efficient as platinum based chemotherapy
•	The role of adjuvant chemotherapy after concomitant chemoradiation remains unclear and should be included in further clinical investigations
versus recommendations in guideline not citing iPD meta-analysis
•	In women with late cervical cancer: combined chemotherapy and radiotherapy is the treatment of choice.
example 2†: antibiotics for acute otitis media54
Impact—targeting treatment to patient groups most likely to benefit
the iPD meta-analysis
•	Six randomised trials, 1643 children aged from 6 months to 12 years
Pertinent results
•	In children younger than 2 years with bilateral acute otitis media, 55% of controls and 30% receiving antibiotics still had pain, fever, or both at 
3–7 days, with a rate difference between these groups of −25% (95% confidence interval −36% to −14%)
•	In children with otorrhoea the rate difference was −36% (95% confidence interval −53% to −19%)
impact on guidelines
•	The UK National Institute for Health and Care Excellence (NICE) guideline on the treatment of otitis media recommended that, in general, 
antibiotics should not be prescribed, or prescription should be delayed. However, immediate antibiotic prescription was recommended for 
children between the ages of 6 months and 2 years with bilateral acute otitis media, and for children of any age with a diagnosis of otorrhoea and 
acute otitis media. Previous systematic reviews identified by the guideline developers, based on summary data, had not shown any differences 
between patient subgroups.
example 3†: monotherapy for epilepsy55
Impact—providing evidence on appropriate outcome measures
the iPD meta-analysis
•	20 randomised trials, 6418 patients with epilepsy treated with monotherapy
•	Network meta-analysis comparing eight antiepileptic drugs
•	Primary outcomes were time to treatment failure and time to 12 month remission from seizures; secondary outcome was time to first seizure
Pertinent results
•	For partial onset seizures (n=4628 (72%) patients), lamotrigine, carbamazepine, and oxcarbazepine provide the best combination of seizure 
control and treatment failure
•	For generalised onset tonic clonic seizures (n=1790 (28%) patients) estimates suggest valproate or phenytoin may provide the best combination 
of seizure control and treatment failure
impact on guidelines
•	Without results from the IPD meta-analysis, the guideline produced by NICE would have been restricted to outcomes reported in the individual 
trials—for example, proportion of seizure-free participants. In contrast, the IPD meta-analysis provided robust evidence on more informative 
outcomes—for example, time to treatment failure, time to 12 month remission from seizures, which were used to inform the guideline 
recommendation
*Information missed when relevant IPD meta-analyses are omitted from guidelines.
†Information gained when relevant IPD meta-analyses are assimilated in guidelines.RESEARCH
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explicitly promoted the use of either the AGREE or the 
GRADE tools in their guidance documents and six 
referred to other methods of appraisal. However, for the 
remainder there was either no mention of the standards 
adhered to in the information available to us (n=5) or no 
information could be found (n=18).
discussion
Overall, based on this sample of 33 IPD meta-analyses 
and 177 matched guidelines, our results indicate that 
systematic reviews, based on IPD, are being under-uti-
lised as a source of the best available evidence within 
clinical guidelines. Little more than a third of the 
guidelines in our sample had cited a recent and rele-
vant IPD meta-analysis, and less than 20% of the 
guidelines had clearly used information from the 
meta-analysis in formulating their recommendations. 
Where such meta-analyses had been cited as part of 
the evidence base, there was often little or no distinc-
tion between an IPD meta-analysis and other non-IPD 
(or non-systematic) reviews or individual randomised 
controlled trials, which were often all assigned the 
highest level of evidence (for example, 1++  or 1A). It 
was also apparent that certain guideline developers 
were more likely to use IPD meta-analyses as the basis 
of their recommendations, as more than half of all the 
guidelines in our sample that cited a meta-analysis 
were produced by only seven guideline development 
groups. It is also unclear why a high proportion of 
guidelines utilised evidence from existing systematic 
reviews of aggregate data (or carried out their own 
analyses based on aggregate data) when relevant sys-
tematic reviews and meta-analyses of IPD were avail-
able, as was the case for each of the guidelines 
included in this study. We believe that a relevant IPD 
meta-analysis should always contribute to clinical 
guidelines if available, unless it is determined to be of 
poor methodological quality, based on limited data or 
superseded by a more recent aggregate data meta-anal-
ysis that includes several new trials. None of these 
exceptions occurred in our sample. Furthermore, even 
when a more recent aggregate data review is available, 
pre-existing IPD meta-analyses may still provide 
important additional information—for example, relat-
ing to the effects of an intervention in different sub-
groups of patients, thus making an important 
contribution to the overall evidence base. Failure to 
assimilate information from IPD meta-analyses may 
lead to less appropriate or limited recommendations 
being made, whereas their uptake may better inform 
the guideline recommendations (see box).
strengths and weaknesses of this study
Ours was not designed to be a comprehensive study but 
rather to provide insight into the uptake of IPD 
meta-analyses by guideline developers. Therefore we 
are aware of certain limitations. Firstly, we restricted 
our searches to three main sources (four for cancer 
guidelines) and so may not have identified all relevant 
guidelines. That many of the IPD meta-analyses identi-
fied were of treatment interventions for cancer (14/33), 
reflects the tradition of IPD meta-analysis in cancer 
research. We also searched an additional source of can-
cer specific guidelines. While we accept that the sample 
may not be entirely representative, we screened more 
than 1100 guidelines in total and included guidelines 
produced by several high profile organisations. Sec-
ondly, the interval between publication of an IPD 
meta-analysis and its subsequent uptake in a guideline 
can vary considerably across guideline development 
groups. Intervals depend on updating schedules or trig-
gers and on available resources, and usually range from 
six months to two years. Therefore, although we consid-
ered the use of a maximum three year time lag between 
publication of the meta-analysis (2008–10) and publi-
cation of the matched guideline (2010–13) as an appro-
priate interval, this does not guarantee that we 
identified all relevant citations. However, we found that 
for the meta-analyses within this sample, many were 
incorporated in guidelines within a year of publication. 
Thirdly, a lack of consistency in the reporting or presen-
tation of guidelines made it difficult to consistently 
attribute recommendations to the evidence supporting 
them. For example, some guidelines omitted details of 
their methods for searching the literature, or provided 
sparse (or no) reference lists. Therefore it was not 
always clear if a relevant meta-analysis had not been 
identified in the searches carried out or whether it 
would have been identified but not included. This may 
reflect fundamental differences in the quality of the 
included guidelines. Although we did not carry out a 
formal quality assessment of all of the included guide-
lines, we found that of the seven guideline development 
groups with guidelines that included more than half of 
the citations of IPD meta-analyses that we identified, 
five indicated that at an organisational level they advo-
cated use of either the AGREE tool51 52 (Alberta Health 
Services, American College of Cardiology Foundation/
American Heart Association, American College of Chest 
Physicians, and Scottish Intercollegiate Guideline Net-
work, SIGN) or the Agency for Healthcare Research and 
Quality guidelines56 57 (American College of Radiology). 
Full reporting of evidence sources and methodology 
used may better enable users to appraise the quality of 
the guideline.58 Finally, a small number of potentially 
eligible guidelines were not freely available. While we 
were able to obtain some of these through our institu-
tion’s library, others were not accessible and could not 
be included. None the less, we believe that the data 
underpinning our review are robust enough to enable 
us to draw qualitatively reliable conclusions about the 
use of IPD meta-analyses in guidelines.
relation to other studies
To our knowledge this is the first review focussing spe-
cifically on the inclusion of IPD meta-analyses in clini-
cal guidelines. With recent calls to improve and increase 
access to trial data, the number of available such 
meta-analyses may increase dramatically. Therefore we 
considered that this study provides an important 
insight into the current situation on the assimilation of 
IPD meta-analyses into clinical guidelines. However, RESEARCH
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others have looked at uptake of systematic reviews in 
guidelines more generally. For example, recent results 
from ongoing work at the UK Cochrane Centre have 
shown that Cochrane reviews across the breadth of 
healthcare areas covered by the collaboration have 
been used to inform findings on the background of clin-
ical guidelines produced by NICE, SIGN, and the World 
Health Organization. The study showed that 1158 
Cochrane reviews had been used in 238 current guide-
lines from those developers.59 Other studies about the 
development of guidelines have been critical of some 
guideline developers, suggesting that the evidence on 
which recommendations are made is sometimes prone 
to bias.60–63 Widespread use of robust and reliable evi-
dence, such as IPD meta-analyses where available, may 
go a long way to averting such criticisms.
A recent systematic review of possible factors pre-
venting uptake of evidence from systematic reviews by 
decision makers cited a lack of awareness and lack of 
familiarity as two of the major barriers.64 For IPD 
meta-analyses in particular, lack of familiarity or 
understanding of the methodology may hinder uptake. 
There may also be additional potential barriers prevent-
ing uptake, which may warrant further investigation. 
Thus for authors of IPD meta-analyses, publication 
alone is not enough to ensure impact on clinical prac-
tice. Many of the meta-analyses included in our sample 
were published in high ranking medical journals and 
yet did not seem to have been considered in clinical 
guidelines. Authors of IPD meta-analyses need to be 
more proactive in making guideline developers aware 
of new results. Current work by the UK Cochrane Centre 
aims to ensure that guideline developers and Cochrane 
review groups work in a more streamlined way to 
improve uptake of new Cochrane reviews. Broader dis-
semination, such as production of policy briefs, press 
releases, and increased use of social media to accom-
pany research findings may also be beneficial. Improv-
ing the understanding of often complex methods and 
findings within the reports of IPD meta-analyses is 
needed. Clearer reporting of such meta-analyses is also 
necessary to ensure that the users of the reviews are 
better able to distinguish IPD meta-analyses from other 
systematic reviews and to facilitate access to methods 
and results arising from these reviews. This should be 
helped by the extension of the preferred reporting items 
for systematic reviews and meta-analyses (PRISMA) 
standards for IPD meta-analysis.
Meaning and implications
It seems clear from our survey that the use of IPD 
meta-analyses in clinical guidelines can, and should, be 
improved. Guideline developers commonly carry out 
their own new systematic reviews and meta-analyses to 
support their guideline recommendations. Indeed, this 
is the WHO recommendation to its guideline develop-
ers.65 Although this ensures an up to date review of 
reported trials, when a recent and relevant IPD 
meta-analysis is available, it may also mean that the 
most robust evidence available is overlooked. One rea-
son for this may be poorer understanding or apprecia-
tion of IPD versus standard systematic reviews. This 
problem has been recognised recently by the Cochrane 
IPD Meta-Analysis Methods Group,10 which has devel-
oped a guidance paper to better enable users of IPD 
meta-analyses to understand them and to appraise their 
quality. Where guideline developers do use the findings 
of such meta-analyses in preference to standard aggre-
gate data systematic reviews, this may lead to a better or 
more nuanced appreciation of the effect of the interven-
tion and may better inform the resulting guideline. In 
the sample of guidelines that we assessed, however, we 
found few examples of this having occurred.
Conclusions
Where IPD meta-analyses are available, of good quality, 
and up to date, they should be used to inform evidence 
based clinical guidelines and thus clinical practice 
more systematically than seems to be the case from this 
study. Increased use of such meta-analyses could 
improve guidelines and ensure that routine patient care 
is based on the most reliable evidence available.
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